✦ LIBER ✦

TREATMENT COMPLETION RATES OF OLANZAPINE AND RISPERIDONE IN LONG ACTING INJECTABLE FORMULATIONS FOR THE TREATMENT OF SCHIZOPHRENIA: A COMPARISON OF SINGLE ARM OPEN-LABEL STUDIES

✍ Scribed by Haya Ascher-Svanum; William Montgmery; Allen Brnabic; Anthony Lawson; Oladapo Tomori; Kristina Coleman; Libby Lynch; Peining Chen; Scott Andersen; David McDonnell

Book ID: 119557650
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 61 KB
Volume: 102
Category: Article
ISSN: 0920-9964
DOI: 10.1016/s0920-9964(08)70832-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost effectiveness of paliperidone palmi

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

✍ Mehnert, Angelika; Nicholl, Deborah; Pudas, Hanna; Martin, Monique; McGuire, Ali 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 767 KB

Cost Effectiveness of Paliperidone Palmi

Cost Effectiveness of Paliperidone Palmitate Versus Risperidone Long-Acting Injectable, Quetiapine and Olanzapine for the Treatment of Patients with Schizophrenia in Colombia

✍ Casallas, C.; Ariza, J.G. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Poster #T8 EFFICACY AND SAFETY OF OLANZA

Poster #T8 EFFICACY AND SAFETY OF OLANZAPINE LONG-ACTING INJECTION IN PATIENTS WITH SCHIZOPHRENIA: A POST-HOC ANALYSIS OF A 6-YEAR MULTINATIONAL SINGLE-ARM OPEN-LABEL STUDY

✍ Anand, Ernie; Berggren, Lovisa; Toth, Agoston; McDonnell, David 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 92 KB

PMH12 Risk of Relapse and Hospitalizatio

PMH12 Risk of Relapse and Hospitalization in the 2-Year Open-Label Treatment of Outpatients with Schizophrenia Randomized to Olanzapine Long-Acting Injection or Oral Olanzapine

✍ D. Novick; H. Ascher-Svanum; J. Bertsch; H. Detke; D. Mcdonnell; M. Witte; J. Ha 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Poster #212 RISK OF RELAPSE AND HOSPITAL

Poster #212 RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE

✍ Novick, Diego; Ascher-Svanum, Haya; Bertsch, Jordan; Detke, Holland C.; McDonnel 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 69 KB

A comparison of the efficacy and safety

A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration

✍ C. W. Ritchie; E. Chiu; S. Harrigan; S. Macfarlane; M. Mastwyk; G. Halliday; H. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 3 views

Background Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effect